Zura Bio (NASDAQ:ZURA) Stock Price Target Cut by Oppenheimer

Zura Bio (NASDAQ:ZURA) had its price objective reduced by equities researchers at Oppenheimer to $5.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer‘s target price points to a potential upside of 247.71% from the stock’s previous close.

ZURA has been the topic of a number of other reports. Wedbush raised their target price on shares of Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Weiss Ratings raised Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 28th. Guggenheim reissued a “buy” rating on shares of Zura Bio in a research report on Friday, October 30th. Finally, Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.50.

Zura Bio Price Performance

Zura Bio stock traded up $0.20 during trading hours on Tuesday, hitting $1.44. 10,362,523 shares of the stock traded hands, compared to its average volume of 1,765,224. Zura Bio has a 1 year low of $0.93 and a 1 year high of $7.44. The firm’s 50 day moving average price is $4.36 and its 200-day moving average price is $5.18. The stock has a market capitalization of $137.80 million, a price-to-earnings ratio of -1.26 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, October 27th. The company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). Research analysts forecast that Zura Bio will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Commodore Capital LP acquired a new position in Zura Bio during the first quarter worth about $19,338,000. Siren L.L.C. grew its holdings in shares of Zura Bio by 187.3% during the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after purchasing an additional 2,434,866 shares during the period. EcoR1 Capital LLC acquired a new stake in Zura Bio during the 1st quarter worth approximately $7,019,000. Stempoint Capital LP acquired a new position in Zura Bio during the first quarter valued at approximately $4,483,000. Finally, Affinity Asset Advisors LLC lifted its position in Zura Bio by 41.4% during the first quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company’s stock valued at $15,258,000 after buying an additional 750,632 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Key Headlines Impacting Zura Bio

Here are the key news stories impacting Zura Bio this week:

• Neutral Sentiment: Options trading was unusually active, with 3,037 call contracts traded—57% above typical volume. This indicates increased activity but does not, by itself, establish whether traders expect shares to rise or fall.
• Negative Sentiment: The TibuSHIELD Phase 2 study missed its primary endpoint, and Zura Bio ended tibulizumab development for hidradenitis suppurativa. The result removes a potential program from the company’s pipeline and is the key negative catalyst in the recent coverage. Zura Bio clinical update and investigation notice Fierce Biotech report
• Negative Sentiment: Investor law firms announced investigations following the trial result. One notice points to Zura Bio’s October 27 SEC filing, which described tibulizumab as advancing in Phase 2, and questions whether investors were adequately informed before the study failed. These are investigations, not findings of wrongdoing, but may add uncertainty and reputational risk. Levi & Korsinsky investigation notice SBS Law investigation notice

About Zura Bio

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.